Shots:

• Glenmark has launched Remogliflozin (SGLT2 inhibitors- 100mg- ) + Vildagliptin (DPP4 inhibitors- 50mg-) + Metformin (500/1000mg) as FDC for the management of T2D in India. The FDC will be marketed under two brand names; Remo MV & Remozen MV
• Glenmark's FDC will improve patient compliance and provide glycemic & extra glycemic benefits to patients with uncontrolled T2D at an affordable cost in India
• The company has received DCGI’s approval for the manufacturing and marketing of the FDC in late Sep’21. Glenmark has become the first company to launch Remogliflozin (100mg) + Vildagliptin (50mg) globally as a fixed-dose combination in 2020

 ­ | Ref: PR Newswire | Image: PR Newswire